Robert M. Weiss MD, FACS, FAAP
Donald Guthrie Professor of Urology; Director, Pediatric Urology
Smooth muscle pharmacology; Signal transduction; Bladder cancer
Current ProjectsUsing nanospheres that contain siRNAs to survivin and VEGF in combination with chemotherapeutic agents to affect growth and spread of bladder cancer in an animal model
We are involved in developing technologies for the prevention and treatment of diseases affecting the bladder.
Extensive Research Description
The Proof of Concept that we are testing is that intravesical instillation of small interference RNA (siRNA) packaged in biodegradable nanospheres provides wide opportunities for the treatment of urologic diseases including transitional cell carcinoma of the bladder (TCC), interstitial cystitis (IC), overactive bladder, and detrusor hyperreflexia.
Because of their robust, gene selective silencing of target protein expression, siRNA oligonucleotides are an attractive therapeutic option with high selectivity and specificity and minimal toxicity to neighboring cells. siRNAs, however, have a relatively short half-life and thus we are addressing the stabilization and intravesical delivery of siRNAs. To achieve this goal, we plan to create and test clinically viable, non-viral nanosphere siRNA complexes that are intravesically
instilled for treatment of diseases of the urinary tract.
We plan to develop and test a number of nanoparticle controlled release systems containing targeting proteins that will stabilize and deliver siRNAs and drugs and initially test these on bladder cancers